Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8618900 | 1.00 | KCNA5 (0.48) | KCNA5HPGDL3MBTL1USP2TSHR | |
| SCHEMBL6327678 | 1.00 | KCNA5 (0.48) | KCNA5HPGDL3MBTL1USP2TSHR | |
| SCHEMBL10930996 | 0.69 | KCNA5 (0.35) | KCNA5 | |
| SCHEMBL5094102 | 0.69 | KCNA5 (0.35) | KCNA5 | |
| SCHEMBL13513362 | 0.68 | GRM4 (0.42) | HPGDL3MBTL1USP2TSHRHTT | |
| SCHEMBL17258152 | 0.67 | USP2 (0.40) | HPGDL3MBTL1USP2TSHRPOLB | |
| SCHEMBL17258153 | 0.67 | USP2 (0.40) | HPGDL3MBTL1USP2TSHRPOLB | |
| SCHEMBL10606036 | 0.65 | — | — | |
| SCHEMBL9153017 | 0.65 | — | — | |
| SCHEMBL1204352 | 0.64 | L3MBTL1 (0.92) | HPGDL3MBTL1LMNANPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
| US-5789587-A | Heterocyclic-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5606054-A | Heterocyclic-fused lactams promote release of growth hormone | MERCK & CO., INC. (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1995016692-A1 | HETEROCYCLIC-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | KCNA5 4070/4885HPGD 1764/4885L3MBTL1 3428/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | KCNA5 4070/4885HPGD 1764/4885L3MBTL1 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.